CLL | Tumor

Imbruvica-Venclexta Combo Superior to Chlorambucil-Obinutuzumab for CLL

June 16th 2021, 9:00pm


The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.

Front-Line Imbruvica-Venclexta Combo May Induce Durable Responses in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

June 10th 2021, 1:00pm


Treatment with this combination was associated with encouraging clinical responses in this patient population.

Calquence and Imbruvica Elicit Similar Survival Results in Previously Treated Patients with Type of Leukemia

June 8th 2021, 4:00pm


Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica.

Cirmtuzumab Plus Imbruvica Led to Increased Response Rates in MCL and CLL

June 7th 2021, 9:00pm


Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Keep Inspiring

April 28th 2021, 12:30pm


Don’t let your disease define you

Imbruvica Plus Ublituximab Safely Improves Response Rate for High-Risk Chronic Lymphocytic Leukemia

April 23rd 2021, 9:00pm


Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.

Gazyva With Chemotherapy Shows Promise for Chronic Lymphocytic Leukemia

April 22nd 2021, 9:00pm


Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.

Your Chronic Lymphocytic Leukemia (CLL) Diagnosis

April 16th 2021, 12:00pm


Navigating life with blood cancer

Sponsored Content: CALQUENCE® (acalabrutinib) for Patients with Chronic Lymphocytic Leukemia (CLL)

March 17th 2021, 12:00pm


An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center

Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia

March 3rd 2021, 7:00pm


Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.